ASH 2022 | Glofitamab as a SOC in third-line DLBCL and its potential in earlier lines of therapy
Adrian Minson, MBBS, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia, comments on the efficacy of glofitamab in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), suggesting that it may become a standard of care (SOC) in the third-line setting, and explaining that this bispecific antibody may be even more effective if used earlier in the treatment algorithm of patients with DLBCL. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Roche: Honoraria, Research Funding; Novartis: Other: Travel support, Research Funding.
